Delving into the Latest Updates on Vandetanib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib (JAN/USAN/INN)

+ [18]

Target

BRK x EGFR x Eph x RET x SRC family x Tie-2 x VEGFR

Mechanism

BRK inhibitors(Tyrosine-protein kinase BRK inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Eph inhibitors(Ephrin receptor inhibitors)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseRespiratory Diseases+ [1]

Active Indication

RET Mutation-Positive Medullary Thyroid CancerAdvanced Thyroid Gland Medullary CarcinomaMetastatic Thyroid Gland Medullary Carcinoma+ [3]

Inactive Indication

Advanced Bile Duct CarcinomaAdvanced breast cancerAdvanced Colorectal Adenocarcinoma+ [57]

Originator Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Active Organization

Sanofi-Aventis Korea Co., Ltd.

Sanofi

Genzyme Corp.

+ [5]

Inactive Organization

Celgene Corp.

AstraZeneca PLC

Dana-Farber Cancer Institute, Inc.

Drug Highest PhaseApproved

First Approval Date

US (06 Apr 2011),

Thyroid Cancer, Medullary

RegulationOrphan Drug (US), Orphan Drug (KR), Orphan Drug (JP)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H24BrFN4O2

InChIKeyUHTHHESEBZOYNR-UHFFFAOYSA-N

CAS Registry443913-73-3

Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI).
The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (Lenvatinib or Sorafenib for differentiated thyroid cancer [which includes papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid cancer]; and Cabozantinib or Vandetanib for medullary thyroid cancer) through adaptive (intermittent) versus conventional (continuous) regimen.

Start Date06 Aug 2018

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

EUCTR2017-002517-64-GB

/ Not yet recruitingPhase 1/2

An open label, single-arm, Phase I/II study of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with hepatocellular carcinoma (HCC) without curative options - VALENCIA

Start Date15 Dec 2017

Sponsor / Collaborator

Biocompatibles UK Ltd.

100 Clinical Results associated with Vandetanib

Login to view more data

100 Translational Medicine associated with Vandetanib

Login to view more data

100 Patents (Medical) associated with Vandetanib

Login to view more data

1,166

Literatures (Medical) associated with Vandetanib

01 Feb 2025·TOXICOLOGY

Disruption of serotonin homeostasis in intestinal organoids provides insights into drug-induced gastrointestinal toxicity

Article

Author: Moretti, Francesca ; Fischer, Audrey ; Vicart, Axel ; Rathfelder, Nicole ; Odermatt, Alex ; Cuttat, Rachel ; Jivkov, Magali ; Wild, Sophia ; Schadt, Heiko S ; Rouseti, Georgia M ; Grimes, Karen ; Schuierer, Sven ; Waldt, Annick ; Dubost, Valerie

Drug-induced gastrointestinal toxicity is a frequent clinical adverse event that needs to be carefully monitored and managed to ensure patient compliance. While preclinical assessment of drug-induced gastrointestinal toxicity mostly relies on animal experimentation, intestinal organoids have gained increasing attention to identify gastrointestinal toxicants in vitro. Nonetheless, current in vitro protocols primarily assess structural alterations induced by drugs, whereas gastrointestinal adverse events can often stem from functional disturbances. Disruption of serotonin signaling in the gastrointestinal tract is associated with impaired motility, as well as nausea and vomiting. We aimed to investigate alterations of serotonin homeostasis in organoids derived from the canine small intestine as a driver of drug-induced gastrointestinal toxicity. Treatment of the organoids with a compound (NVS-1) inducing acute gastrointestinal toxicity in dogs as well as with three tyrosine kinase inhibitors with known preclinical and clinical gastrointestinal adverse effects (afatinib, crizotinib and vandetanib) led to increased supernatant serotonin levels. Mechanistic assays showed that, while NVS-1 and afatinib stimulate serotonin release, crizotinib and vandetanib inhibit serotonin re-uptake via direct inhibition of the serotonin re-uptake transporter. Using a data mining approach, we further suggest that inhibition of serotonin re-uptake could contribute to gastrointestinal toxicity observed with multiple marketed drugs. In conclusion, we present the implementation of a novel in vitro gastrointestinal toxicity endpoint that could complement current methods and serve as a mechanistic and predictive/screening tool for drug-induced gastrointestinal toxicity.

01 Dec 2024·TOXICOLOGY

ToxProfiler: A novel human-based reporter assay for in vitro chemical safety assessment

Article

Author: Hendriks, Giel ; Ter Braak, Bas ; Jamalpoor, Amer ; ter Braak, Bas ; Loonstra-Wolters, Liesanne ; Elbertse, Kim ; Osterlund, Torben

In vitro chemical safety assessment often relies on simple and general cytotoxicity endpoint measurements and fails to adequately predict human toxicity. To improve the in vitro chemical safety assessment, it is important to understand the underlying mechanisms of toxicity. Here we introduce ToxProfiler, a novel human-based reporter assay that quantifies the chemical-induced stress responses at a single-cell level and reveals the toxicological mode-of-action (MoA) of novel drugs and chemicals. The assay accurately measures the activation of seven major cellular stress response pathways (oxidative stress, cell cycle stress, endoplasmic reticulum stress, ion stress, protein stress, autophagy and inflammation) that play a role in the adaptive responses prior to cellular toxicity. To assess the applicability of the assay in predicting the toxicity MoA of chemicals, we tested a set of 100 chemicals with well-known in vitro and in vivo toxicological profiles. Concentration response modeling and point-of-departure estimation for each reporter protein allowed for chemical potency ranking and revealed the primary toxicological MoA of chemicals. Furthermore, the assay could effectively group chemicals based on their shared toxicity signatures and link them to specific toxicological targets, e.g. mitochondrial toxicity and genotoxicity, and different human pathologies, including liver toxicity and cardiotoxicity. Overall, ToxProfiler is a quantitative in vitro reporter assay that can accurately provide insight into the toxicological MoA of compounds, thereby assisting in the future mechanism-based safety assessment of chemicals.

01 Dec 2024·Molecular diversity

Computational discovery of novel FYN kinase inhibitors: a cheminformatics and machine learning-driven approach to targeted cancer and neurodegenerative therapy

Article

Author: Gopal, Dhanushya ; Muthuraj, Rajesh ; Chandrasekaran, Jaikanth ; Balaya, Rex Devasahayam Arokia ; Kanekar, Saptami ; Ahmed, Iqrar

In this study, we explored the potential of novel inhibitors for FYN kinase, a critical target in cancer and neurodegenerative disorders, by integrating advanced cheminformatics, machine learning, and molecular simulation techniques. Our approach involved analyzing key interactions for FYN inhibition using established multi-kinase inhibitors such as Staurosporine, Dasatinib, and Saracatinib. We utilized ECFP4 circular fingerprints and the t-SNE machine learning algorithm to compare molecular similarities between FDA-approved drugs and known clinical trial inhibitors. This led to the identification of potential inhibitors, including Afatinib, Copanlisib, and Vandetanib. Using the DrugSpaceX platform, we generated a vast library of 72,196 analogues from these leads, which after careful refinement, resulted in 6008 promising candidates. Subsequent clustering identified 48 analogues with significant similarity to known inhibitors. Notably, two candidates derived from Vandetanib, DE27123047 and DE27123035, exhibited strong docking affinities and stable binding in molecular dynamics simulations. These candidates showed high potential as effective FYN kinase inhibitors, as evidenced by MMGBSA calculations and MCE-18 scores exceeding 50. Additionally, our exploration into their molecular architecture revealed potential modification sites on the quinazolin-4-amine scaffold, suggesting opportunities for strategic alterations to enhance activity and optimize ADME properties. Our research is a pioneering effort in drug discovery, unveiling novel candidates for FYN inhibition and demonstrating the efficacy of a multi-layered computational strategy. The molecular insights gained provide a pathway for strategic refinements and future experimental validations, setting a new direction in targeted drug development against diseases involving FYN kinase.

15

News (Medical) associated with Vandetanib

30 Sep 2024

·www.fda.gov

FDA approves selpercatinib for medullary thyroid cancer with a RET mutation

On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. Selpercatinib received accelerated approval for this indication for patients 12 years of age and older in 2020. On May 29, 2024, the FDA granted accelerated approval for this indication to pediatric patients 2 years of age and older. Efficacy was evaluated in LIBRETTO-531 (NCT04211337), a randomized, multicenter, open-label study in adults and adolescents with advanced or metastatic RET-mutant MTC. Patients were randomized (2:1) to receive either selpercatinib (160 mg twice daily) or physicians’ choice of cabozantinib (140 mg once daily) or vandetanib (300 mg once daily). Patients were stratified based on RET mutation (M918T vs. other) and intended treatment if randomized to the control arm (cabozantinib vs. vandetanib). The main efficacy outcome measure was progression-free survival (PFS), as determined by a blinded independent review committee according to RECIST v1.1. Median PFS was not reached (NR) (95% CI: not evaluable [NE], NE) in the selpercatinib arm and 16.8 months (95% CI: 12.2, 25.1) in the cabozantinib/vandetanib arm (Hazard Ratio 0.280 [95% CI: 0.165, 0.475] p-value <0.0001). The clinical benefit of selpercatinib was supported by a pre-specified analysis of patient-reported comparative side effect impact; patients in the selpercatinib arm reported less time with severe side effect bother than those receiving cabozantinib or vandetanib. The most common adverse reactions (≥25%) were hypertension, edema, dry mouth, fatigue, and diarrhea. The most common Grade 3 or 4 laboratory abnormalities (≥5%) were decreased lymphocytes, increased alanine aminotransferase (ALT), decreased neutrophils, increased alkaline phosphatase (ALP), increased blood creatinine, decreased calcium, and increased aspartate aminotransferase (AST). The recommended selpercatinib dose for pediatric patients 2 to less than 12 years of age is based on body surface area and is based on weight for patients 12 years of age and older. See the prescribing information for specific dosing information. Expedited Programs This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted priority review, breakthrough designation, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X: @FDAOncologyExternal Link Disclaimer. Content current as of: 09/30/2024 Regulated Product(s) Drugs Content current as of: 09/30/2024 Regulated Product(s) Drugs Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Drug ApprovalPriority ReviewAccelerated ApprovalOrphan DrugClinical Result

09 Aug 2024

·www.fda.gov

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

On May 8, 2020, the Food and Drug Administration granted accelerated approval to selpercatinib (RETEVMO, Eli Lilly and Company) for the following indications: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Efficacy was investigated in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001) in patients whose tumors had RET alterations. Identification of RET gene alterations was prospectively determined in local laboratories using either next generation sequencing, polymerase chain reaction, or fluorescence in situ hybridization. The main efficacy outcome measures were overall response rate (ORR) and response duration determined by a blinded independent review committee using RECIST 1.1. Efficacy for RET-fusion-positive NSCLC was evaluated in 105 adult patients, previously treated with platinum chemotherapy. The ORR was 64% (95% CI: 54%, 73%); 81% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 39 patients who never received systemic treatment. The ORR for these patients was 85% (95% CI: 70%, 94%); 58% of responding patients had responses lasting 6 months or longer. Efficacy for advanced or metastatic RET-mutant MTC was investigated in adults and pediatric patients (≥12 years of age). The trial enrolled patients previously treated with cabozantinib, vandetanib, or both, and patients who had not received these drugs. The ORR for the 55 previously treated patients was 69% (95% CI: 55%, 81%); 76% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 88 patients not previously treated with an approved therapy for MTC. The ORR for these patients was 73% (95% CI: 62%, 82%); 61% of responding patients had responses lasting 6 months or longer. Efficacy for RET fusion-positive thyroid cancer was evaluated in adults and pediatric patients (≥12 years of age). The trial enrolled 19 patients who were radioactive iodine-refractory (if appropriate) and had received another prior systemic treatment, and 8 patients who were RAI-refractory and had not received any additional therapy. The ORR for the 19 previously treated patients was 79% (95% CI: 54%, 94%); 87% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 8 patients who received RAI and no other subsequent therapy. All 8 patients responded (95% CI: 63%, 100%) and 75% had responses lasting 6 months or longer. The most common adverse reactions, including laboratory abnormalities, (≥ 25%) were increased aspartate aminotransferase, increased alanine aminotransferase, increased glucose, decreased leukocytes, decreased albumin, decreased calcium, dry mouth, diarrhea, increased creatinine, increased alkaline phosphatase, hypertension, fatigue, edema, decreased platelets, increased total cholesterol, rash, decreased sodium, and constipation. The recommended selpercatinib dose is weight based—120 mg for patients less than 50 kg, and 160 mg for those 50 kg or greater. Selpercatinib is taken orally twice daily with or without food; or with food when co-administered with a proton pump inhibitor. View full prescribing information for RETEVMO. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was approved 3 months prior to the FDA goal date. This application was granted accelerated approval based on overall response rate and response duration. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials. This application was granted priority review, breakthrough therapy, and orphan drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncologyExternal Link Disclaimer.

Clinical ResultDrug ApprovalPriority ReviewBreakthrough TherapyAccelerated Approval

09 Aug 2024

·www.fda.gov

FDA approves pralsetinib for RET-altered thyroid cancers

On December 1, 2020, the Food and Drug Administration approved pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Efficacy was investigated in a multicenter, open label, multi-cohort clinical trial (ARROW, NCT03037385) in patients whose tumors had RET gene alterations. Identification of RET gene alterations was prospectively determined in local laboratories using either next generation sequencing, fluorescence in situ hybridization, or other tests. The main efficacy outcome measures were overall response rate (ORR) and response duration determined by a blinded independent review committee using RECIST 1.1. Efficacy for advanced or metastatic RET-mutant MTC was evaluated in 55 patients who received prior cabozantinib or vandetanib. The ORR for these patients was 60% (95% CI: 46%, 73%); 79% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 29 patients with RET-mutant MTC who did not receive prior cabozantinib or vandetanib. The ORR was 66% (95% CI: 46%, 82%); 84% of patients had responses lasting 6 months or longer. Efficacy for patients with RET fusion-positive thyroid cancer was evaluated in 9 patients who were radioactive iodine-refractory. The ORR was 89% (95% CI: 52%, 100%); all responding patients had responses lasting 6 months or longer. The most common adverse reactions (≥25%) were constipation, hypertension, fatigue, musculoskeletal pain, and diarrhea. The most common Grade 3-4 laboratory abnormalities (≥2%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased phosphate, decreased calcium (corrected), decreased sodium, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), decreased platelets, and increased alkaline phosphatase. The recommended pralsetinib dose in adults and pediatric patients 12 years and older is 400 mg orally once daily on an empty stomach with no food intake for at least 2 hours before and at least 1 hour after taking pralsetinib. View full prescribing information for GAVRETO. This review used the Real-Time Oncology Review (RTOR) pilot program and Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application 3 months ahead of the FDA goal date. This application was granted accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This application was granted priority review, breakthrough therapy, and orphan drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncologyExternal Link Disclaimer. Content current as of: 12/01/2020 Regulated Product(s) Drugs Prescription Drugs 12/01/2020 Drugs Prescription Drugs Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Drug ApprovalPriority ReviewClinical ResultAccelerated ApprovalOrphan Drug

100 Deals associated with Vandetanib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06407	Vandetanib	L01XE12	DB05294

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
RET Mutation-Positive Medullary Thyroid Cancer	EU	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	IS	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	LI	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	NO	Sanofi	01 Feb 2023
Advanced Thyroid Gland Medullary Carcinoma	KR	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Metastatic Thyroid Gland Medullary Carcinoma	KR	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Thyroid Cancer, Medullary	US	Genzyme Corp.	06 Apr 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	Phase 3	US	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	US	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	US	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	US	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	CN	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	JP	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	JP	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	JP	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	JP	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	BR	Genzyme Corp.	17 Sep 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03291379 (VEROnA, Pubmed) Manual	Phase 1	Neoplasms	8	Vandetanib-Eluting Radiopaque Embolics	wusaikkymw(wcyqscsmwa) = There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. odjftaomdv (jcswvrrjyq )	Positive	05 May 2022
NCT01934335 (CTgov)	Phase 2	Invasive Mammary Carcinoma	12	Vandetanib (Vandetanib)	sxjzzerqus(cccwwcghyl) = lqyxjlywfd gqjrmrtqbs (buclfbpncr, fnxzxylyed - mwtdkhllff) View more	-	01 Nov 2021
				Placebo (Placebo)	sxjzzerqus(cccwwcghyl) = ushvypnkww gqjrmrtqbs (buclfbpncr, hqlwhzzthl - xekxzxejiw) View more
NCT01586624 (CTgov)	Phase 1	Non-Small Cell Lung Cancer	61	Selumetinib+Vandetanib (Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib))	hqvzsutvrk(wmtftlybpp) = kiadqbujvb wkdewvmlah (gijhcnqdfr, lixyarzbwp - uxvsplytek) View more	-	07 Oct 2021
				Selumetinib+Vandetanib (Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib))	hqvzsutvrk(wmtftlybpp) = gucvtkasmf wkdewvmlah (gijhcnqdfr, duzuqruoii - jdfafayfeq) View more
NCT01582191 (Pubmed \| ESMO Open) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	80	vandetanib+everolimus	xjvaghghuz(tuvniiijwg) = qqpkvewwqw xicspowngi (avflrgzcao, 3.4 - 7.3) View more	Positive	01 Apr 2021
NCT03291379 (VEROnA, CTgov)	Early Phase 1	Hepatocellular Carcinoma \| Metastatic Colorectal Carcinoma	8	BTG-002814	bzxqxrqtkd(sfwwldadhi) = zxedchtbfe xtzlmabxdt (pssqkeiknh, zbgemswdfi - xltkgtyzlo) View more	-	03 Feb 2021
NCT03630120 (CTgov)	Phase 2	Thyroid Cancer, Follicular \| Differentiated Thyroid Gland Carcinoma \| Papillary thyroid cancer ... View more	6	Sorafenib+Lenvatinib (Standard of Care: DTC)	mrurltawvm(umazwkveaj) = fxtvsjnytd otrncsosrg (jbtbblmanz, rvandjhtgc - ebjkyfadgx) View more	-	22 Jan 2021
				Sorafenib+Lenvatinib (Adaptive Care: DTC)	mrurltawvm(umazwkveaj) = ehrhojqdur otrncsosrg (jbtbblmanz, ozlqatgyul - kiybbcttqk) View more
NCT01183559 (CTgov)	Phase 1	Esophageal Carcinoma \| Locally Advanced Gastroesophageal Junction Adenocarcinoma	9	External Beam Radiation Therapy (RT)+carboplatin+Vandetanib+Paclitaxel+5 Fluorouracil (FU)	esxwmynukk(hqitciohjx) = jxkjyhzaxq bmbdrnanqs (jbfcsvazsw, pftqptgbuv - fhyxmxxgmb) View more	-	22 Jan 2021
NCT01414426 (CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Verrucous Carcinoma \| Precancerous Conditions	20	biopsy+vandetanib (Arm I (Chemoprevention))	eyzdwvmeyk(mbqjcvolid) = hgslnrklaz efimlrtzhf (uiwqjxnwes, oxnepfvqul - ygtkqgrvys) View more	-	14 Jan 2021
				placebo (Arm II (Placebo))	eyzdwvmeyk(mbqjcvolid) = tmxckxqwlz efimlrtzhf (uiwqjxnwes, pxglozeqgj - aczxhbvxhv) View more
NCT00514046 (CTgov)	Phase 1/2	Multiple Endocrine Neoplasia Type 2b \| Familial Medullary Thyroid Carcinoma \| Thyroid Cancer, Medullary	17	Vandetanib (All Participants)	drlkjcwtfv(fgaifagdma) = fkettwumqv vyghlgwbzc (vtshmxbgqo, flmgemjokg - kmfykxkmyi) View more	-	22 Dec 2020
				Vandetanib (Vandetanib: First 100 mg/m^2, Then 150 mg/m^2)	xwxzbtncdv(ozpqthwwij) = ljnmzlfikf zaidaafzsh (aoyfdzpwkp, iryasrppdy - yfkjjhuixm) View more
NCT02530411 (FURVA, ESMO2020)	Phase 2	Estrogen receptor positive breast cancer	165	Vandetanib 300mg + Fulvestrant 500mg	ohmcqpaasj(tzewnyikia) = fsqiilukwq tprfklqtdl (nzztrswcsz ) View more	Negative	18 Sep 2020
				Placebo + Fulvestrant 500mg	ohmcqpaasj(tzewnyikia) = vxxfqjwmqf tprfklqtdl (nzztrswcsz ) View more